Please see our Privacy Notice for details of your data protection rights.
Mike Ryan, executive director at the World Health Organisation, said earlier this months that "there is a long way to go" before the world gets its first approved vaccine.
The British government, in the meantime, has signed a deal with pharmaceutical giants GlaxoSmithKline (GSK) and Sanofi Pasteur for 60 million doses of a potential Covid-19 vaccine if the tests prove to be successful.
The human clinical trial of indigenously developed Covaxin, a possible vaccine against coronavirus, began at a hospital, officials said on Friday.
Six weeks later, all of the animals were exposed to the SARS-CoV-2 virus.
Tests have shown that the vaccine promotes the creation of protective antibodies. All 20 animals that received the placebo developed high levels of virus in their lungs and nasal swabs.
"We look forward to the results of the clinical trials that will determine the safety and immunogenicity, and ultimately the efficacy, of the Ad26.COV2.S vaccine in humans".
"The findings give us confidence as we progress our vaccine development and upscale manufacturing in parallel, having initiated a Phase 1/2a trial in July with the intention to move into a Phase 3 trial in September".
The six non-human primates that were given the jab had no detectible virus in the lower respiratory tract after exposure to SARS-CoV-2, the study said.
The company plans to take up the question of one or two doses in its phase 1 trial.
A group of scientists led by Beth Israel Deaconess Medical Center (BIDMC) immunologist Dan H. Barouch is developing a single-shot vaccine for COVID-19.
Russian Federation is targeting to be the first in the world to approve a COVID-19 vaccine for mass use in less than two weeks despite safety and efficacy concerns, according to a CNN report.
The US is backing the effort from scientific firm Johnson & Johnson, with $456 million in funding.